SVRA Stock Overview
A clinical stage biopharmaceutical company, focuses on rare respiratory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Savara Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.13 |
| 52 Week High | US$5.70 |
| 52 Week Low | US$2.82 |
| Beta | 1.02 |
| 11 Month Change | -12.32% |
| 3 Month Change | -29.02% |
| 1 Year Change | -13.77% |
| 33 Year Change | 163.03% |
| 5 Year Change | 195.28% |
| Change since IPO | -64.27% |
Recent News & Updates
Recent updates
Savara: Trial Successful, But I'm Only Half Convinced
Sep 09Savara: Today's Data 'Win' Rouses Market All Too Briefly
Jun 26Savara: The Binary Bet On Phase 3 Data
Jun 07Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?
Dec 14
Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Feb 16Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Oct 12Savara's rare lung disorder drug gets promising innovative medicine status in UK
Aug 26Savara GAAP EPS of -$0.06 in-line
Aug 11Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?
Jan 24Is Savara (NASDAQ:SVRA) A Risky Investment?
Jul 05Savara: They Failed Once, But They Are Trying Again
Jun 07The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares
Mar 17Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares
Feb 26Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex
Nov 24Savara EPS misses by $0.01
Nov 05Shareholder Returns
| SVRA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.7% | -6.5% | -1.0% |
| 1Y | -13.8% | 14.6% | 30.3% |
Return vs Industry: SVRA underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: SVRA underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| SVRA volatility | |
|---|---|
| SVRA Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SVRA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SVRA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 37 | Matt Pauls | www.savarapharma.com |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
Savara Inc. Fundamentals Summary
| SVRA fundamental statistics | |
|---|---|
| Market cap | US$504.56m |
| Earnings (TTM) | -US$82.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.5x
P/E RatioIs SVRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SVRA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$67.48m |
| Gross Profit | -US$67.48m |
| Other Expenses | US$15.46m |
| Earnings | -US$82.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.48 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 13.3% |
How did SVRA perform over the long term?
See historical performance and comparison